Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: NeoPhore prepares for its first clinical trial, Laverock builds a team for its next financing and GH Research adds late-stage depression expertise.
ADVERTISEMENT
London-based Boltz has raised $110 million (€100 million) in a Series A led by Bessemer Venture Partners to expand its AI platform for designing small-molecule drugs and therapeutic proteins. The financing comes as the company reports rapidly growing adoption among major pharmaceutical companies.
The British Business Bank has surpassed £1 billion in cumulative support for the U.K. life sciences sector, reaching £1.13 billion (€1.36 billion) through commitments to specialist investment funds and direct investments in biotech and medtech companies.
German biotech Priavoid has missed the primary efficacy endpoint in a Phase 2 trial of its oral Alzheimer’s drug PRI-002. However, the company reported encouraging signs of cognitive benefit in longer-term exploratory analyses, leaving the future of its experimental treatment open.
U.S. biotech Vertex Pharmaceuticals has extended its drug discovery partnership with Oxford-based Genomics Limited by an additional four years in a deal the U.K. company says could exceed $220 million (€200 million).
Cologne-based DISCO Pharmaceuticals has signed a cancer drug discovery deal with AbbVie, securing $40 million (€36.5 million) upfront and potentially up to $2.5 billion (€2.3 billion) in additional payments. It is the German biotech’s second major pharma partnership this year, following its January agreement with Amgen.
London-based Isomorphic Labs has raised $5 billion (€4.5 billion) in a Series C co-led by Greenoaks and Sequoia Capital, just six months after securing $2.1 billion. The latest financing takes the Alphabet-backed AI drug developer’s disclosed fundraising to $7.7 billion across three rounds since March 2025.
Dutch biotech AmyriAD Therapeutics has added a second clinical-stage drug in six weeks, buying worldwide rights to the Alzheimer’s candidate AD04 from Miami-based ADvantage Therapeutics on undisclosed terms. It plans a Phase 2b trial in mild Alzheimer’s disease, though ADvantage’s own European Phase 2b is paused.
This week in our news roundup: Cellectis’ shift toward in vivo gene editing comes with steep workforce cuts, while Sanofi and AstraZeneca add new technologies through deals. Elsewhere, respiratory developers plan a merger, Lithuania’s Biomatter raises funding and Zealand seeks partners for its rare-disease medicines.
Danish biotech Commit Biologics has completed a $60 million (€54 million) seed financing round to advance its first complement-powered immune engager toward clinical trials. The closing follows the nomination of its first drug candidate and several senior appointments as the company prepares to enter the clinic.










